

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2381353/marcus-koch-publications-by-citations.pdf>  
**Version:** 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97 papers	3,210 citations	32 h-index	54 g-index
104 ext. papers	3,714 ext. citations	6.3 avg, IF	5.11 L-index

#	Paper	IF	Citations
97	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , <b>2013</b> , 13, 128	3.1	289
96	Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. <i>Journal of the Neurological Sciences</i> , <b>2008</b> , 267, 3-16	3.2	178
95	Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. <i>Neuroepidemiology</i> , <b>2013</b> , 40, 195-210	5.4	138
94	The natural history of secondary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 1039-43	5.5	135
93	Tremor in multiple sclerosis. <i>Journal of Neurology</i> , <b>2007</b> , 254, 133-45	5.5	135
92	An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. <i>Nature Communications</i> , <b>2016</b> , 7, 11312	17.4	121
91	The natural history of primary progressive multiple sclerosis. <i>Neurology</i> , <b>2009</b> , 73, 1996-2002	6.5	111
90	Epigenetic changes in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 35-43	15	106
89	Seizures in multiple sclerosis. <i>Epilepsia</i> , <b>2008</b> , 49, 948-53	6.4	87
88	Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2008</b> , 28, 1645-51	7.3	81
87	Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. <i>Brain</i> , <b>2007</b> , 130, 1626-30	11.2	81
86	Therapeutic potential of fluoxetine in neurological disorders. <i>CNS Neuroscience and Therapeutics</i> , <b>2008</b> , 14, 153-64	6.8	78
85	Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. <i>Journal of Neurology</i> , <b>2006</b> , 253, 483-7	5.5	71
84	Progression in multiple sclerosis: further evidence of an age dependent process. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 255, 35-41	3.2	70
83	Cigarette smoking and progression in multiple sclerosis. <i>Neurology</i> , <b>2007</b> , 69, 1515-20	6.5	70
82	Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. <i>Neurology</i> , <b>2010</b> , 74, 1822-6	6.5	69
81	Plasma homocysteine levels in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2006</b> , 77, 189-92	5.5	68

80	Validity of four screening scales for major depression in MS. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1064-715		63
79	Depression in multiple sclerosis: a long-term longitudinal study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 76-83		58
78	Plasma lipid peroxidation and progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 529-33	6	55
77	Parity and secondary progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2009</b> , 80, 676-8	5.5	53
76	Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. <i>Archives of Neurology</i> , <b>2008</b> , 65, 607-11		52
75	Environmental factors and their regulation of immunity in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2013</b> , 324, 10-6	3.2	51
74	Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. <i>Journal of Neurology</i> , <b>2008</b> , 255, 875-80	5.5	48
73	Pharmacologic treatment of depression in multiple sclerosis. <i>The Cochrane Library</i> , <b>2011</b> , CD007295	5.2	40
72	Fatigue, depression and progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 815-22	5	36
71	Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter. <i>PLoS ONE</i> , <b>2010</b> , 5, e10811	3.7	36
70	Treatment trials in progressive MS--current challenges and future directions. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 496-503	15	35
69	Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. <i>CNS Neuroscience and Therapeutics</i> , <b>2013</b> , 19, 737-44	6.8	34
68	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. <i>Journal of the Neurological Sciences</i> , <b>2015</b> , 358, 131-7	3.2	33
67	Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. <i>Trends in Molecular Medicine</i> , <b>2013</b> , 19, 23-30	11.5	33
66	Cerebral white matter blood flow and energy metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1282-9	5	32
65	Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 797-800	6	32
64	Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. <i>Nature Communications</i> , <b>2017</b> , 8, 1990	17.4	31
63	Uric acid in multiple sclerosis. <i>Neurological Research</i> , <b>2006</b> , 28, 316-9	2.7	29

62	Lack of association between serum uric acid levels and outcome in acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , <b>2012</b> , 319, 51-5	3.2	28
61	Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study. <i>European Journal of Neurology</i> , <b>2009</b> , 16, 348-52	6	27
60	MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 48-60	4	25
59	Factors associated with the risk of secondary progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 799-803	5	23
58	Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1543-1556	5	21
57	Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123824	3.7	21
56	Hemorrhagic encephalopathy associated with COVID-19. <i>Journal of Neuroimmunology</i> , <b>2020</b> , 346, 577326	5	21
55	Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. <i>The Cochrane Library</i> , <b>2009</b> , CD006453	5.2	18
54	Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 537-40	5.5	18
53	T2 lesions and rate of progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2010</b> , 17, 1471-5	6	18
52	Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 159-65	5	18
51	Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model. <i>FEMS Microbiology Letters</i> , <b>2005</b> , 242, 203-8	2.9	18
50	Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?. <i>European Journal of Neurology</i> , <b>2009</b> , 16, 819-22	6	17
49	Plasma S100beta and NSE levels and progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 252, 154-8	3.2	16
48	Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1540-1549	5	16
47	The natural history of early versus late disability accumulation in primary progressive MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 615-21	5.5	15
46	Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 244, 123-6	3.2	14
45	Hand dexterity and direct disease related cost in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 341, 51-4	3.2	13

44	Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , <b>2013</b> , 128, e26-9	3.8	13
43	Timing of birth and disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 793-8	5	13
42	Serum NSE level and disability progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2015</b> , 350, 46-50	3.2	12
41	Jerking & confused: Leucine-rich glioma inactivated 1 receptor encephalitis. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 289, 84-6	3.5	12
40	Disease onset in familial and sporadic primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 694-700	5	12
39	Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 651-658	6	11
38	The promise of futility trials in neurological diseases. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 300-5	15	11
37	Progression in familial and nonfamilial MS. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 300-6	5	11
36	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 96, e111-e120	6.5	11
35	A fatal demyelinating illness in a young woman 10 weeks post partum. <i>Lancet Neurology</i> , <b>2005</b> , 4, 129-34	24.1	10
34	Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e358	9.1	9
33	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. <i>Neurology</i> , <b>2007</b> , 68, 1163; author reply 1163-4	6.5	9
32	Subacute sclerosing panencephalitis in pregnancy. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 366-75	25.5	8
31	Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients. <i>European Radiology</i> , <b>2008</b> , 18, 1736-40	8	8
30	Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 1210-5	6	7
29	Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2619-2624	5.5	5
28	Surgical resection in metastatic spinal cord compression. <i>Lancet</i> , <b>2006</b> , 367, 109; author reply 109-110	10	5
27	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 90, 940-948	9.4	5

26	Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2021</b> , 18, 387-400	6.4	5
25	Smoking does not influence disability accumulation in primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 624-630	6	4
24	Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2019</b> , 334, 576974	3.5	4
23	Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , <b>2008</b> , 63, 125-6; author reply 126-7	9.4	4
22	Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial. <i>Neurology</i> , <b>2021</b> , 96, e2313-e2322	6.5	4
21	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1560-e1570	6.5	4
20	Treatment of seizures in multiple sclerosis. <i>The Cochrane Library</i> , <b>2009</b> , CD007150	5.2	3
19	Pharmacologic treatment of depression in multiple sclerosis <b>2008</b> ,		3
18	Paroxysmal focal dystonia with sensory symptoms secondary to cortical oligoastrocytoma. <i>Journal of Neurology</i> , <b>2006</b> , 253, 1227-8	5.5	3
17	Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 8587-8600	6.6	3
16	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 2115-2120	6	3
15	A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1864-1874	5	2
14	Genetic characterization of measles virus genotype D6 subacute sclerosing panencephalitis case, Alberta, Canada. <i>Journal of NeuroVirology</i> , <b>2018</b> , 24, 720-729	3.9	2
13	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. <i>Neurology</i> , <b>2021</b> , 97, e1334-e1342	6.5	2
12	Primary and secondary progressive MS have a similar age at onset of progression - Commentary. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 642-643	5	1
11	Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures <b>2007</b> ,		1
10	Irreversible neurological worsening following high-dose corticosteroids in advanced progressive multiple sclerosis. <i>Clinical Neuropharmacology</i> , <b>2006</b> , 29, 18-9	1.4	1
9	Advanced Analysis of Diffusion Tensor Imaging Along With Machine Learning Provides New Sensitive Measures of Tissue Pathology and Intra-Lesion Activity in Multiple Sclerosis. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 634063	5.1	1

8	An enrichment strategy for clinical trials in SPMS. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1884-1893	5	1
7	Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	1
6	Serum HGF and APN2 are associated with disability worsening in SPMS.. <i>Journal of Neuroimmunology</i> , <b>2021</b> , 364, 577803	3.5	0
5	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211031801	5	0
4	CSF oligoclonal bands and progression of disability in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2008</b> , 15, e24-e24	6	
3	Reply: Hyperglycaemia and the outcome of stroke. <i>Brain</i> , <b>2007</b> , 130, e86-e86	11.2	
2	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211063623	5	
1	Clinical Reasoning: A pregnant woman with chin numbness. <i>Neurology</i> , <b>2019</b> , 92, e996-e999	6.5	